Kim Martha, Jung Mi-Young, Lee Do-Yeon, Ahn So Min, Lee Gyeong Min, Park Choul Yong
Department of Ophthalmology, Dongguk University Ilsan Hospital, Goyang 10326, Republic of Korea.
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea.
Pharmaceutics. 2024 Dec 16;16(12):1604. doi: 10.3390/pharmaceutics16121604.
This review aims to examine existing research on the development of ocular drug delivery devices utilizing hyaluronic acid (HA). Renowned for its exceptional biocompatibility, viscoelastic properties, and ability to enhance drug bioavailability, HA is a naturally occurring biopolymer. The review discussed specific mechanisms by which HA enhances drug delivery, including prolonging drug residence time on ocular surfaces, facilitating controlled drug release, and improving drug penetration through ocular tissues. By focusing on these unique functionalities, this review highlights the potential of HA-based systems to revolutionize ocular treatment. Various fabrication techniques for HA-based ocular drug delivery systems, including hydrogels, nanoparticles, and microneedles, are discussed, highlighting their respective advantages and limitations. Additionally, this review explores the clinical applications of HA-based devices in treating a range of ocular diseases, such as dry eye syndrome, glaucoma, retinal disorders, and ocular infections. By comparing the efficacy and safety profiles of these devices with traditional ocular drug delivery methods, this review aims to provide a comprehensive understanding of the potential benefits and challenges associated with HA-based systems. Moreover, this review discusses current limitations and future directions in the field, such as the need for standardized fabrication protocols, long-term biocompatibility studies, and large-scale clinical trials. The insights and advancements presented in this review aim to guide future research and development efforts, ultimately enhancing the effectiveness of ocular drug delivery and improving patient outcomes.
本综述旨在研究利用透明质酸（HA）开发眼部给药装置的现有研究。HA是一种天然存在的生物聚合物，以其卓越的生物相容性、粘弹性以及提高药物生物利用度的能力而闻名。该综述讨论了HA增强药物递送的具体机制，包括延长药物在眼表的停留时间、促进药物的控释以及改善药物通过眼组织的渗透。通过关注这些独特的功能，本综述强调了基于HA的系统彻底改变眼部治疗的潜力。讨论了基于HA的眼部给药系统的各种制备技术，包括水凝胶、纳米颗粒和微针，突出了它们各自的优点和局限性。此外，本综述探讨了基于HA的装置在治疗一系列眼部疾病中的临床应用，如干眼症、青光眼、视网膜疾病和眼部感染。通过将这些装置的疗效和安全性与传统眼部给药方法进行比较，本综述旨在全面了解与基于HA的系统相关的潜在益处和挑战。此外，本综述讨论了该领域当前的局限性和未来方向，如对标准化制备方案、长期生物相容性研究和大规模临床试验的需求。本综述中提出的见解和进展旨在指导未来的研发工作，最终提高眼部给药的有效性并改善患者预后。
